Kaposi sarcoma is an intermediate-grade vascular tumor linked to human herpesvirus 8 (HHV-8). Its spindle cells form slit-like spaces, often with red blood cell leakage and hemosiderin. HHV-8 LANA staining helps identify it, while its behavior sets it apart from both benign lesions and aggressive angiosarcoma.

Multiple Choice

Which vascular neoplasm is an intermediate-grade lesion caused by human herpesvirus 8?

Kaposi sarcoma is the vascular neoplasm caused by human herpesvirus 8, and it’s considered intermediate-grade because it can invade locally and metastasize variably—more aggressive than benign vascular lesions but not uniformly as malignant as angiosarcoma. Histologically, it shows spindle-cell proliferation forming slit-like vascular spaces with extravasated red blood cells and hemosiderin, and tumor cells typically test positive for HHV-8 latent nuclear antigen (LANA). This HHV-8 association is a hallmark that helps distinguish KS from other vascular tumors: pyogenic granuloma is benign and lobular, hemangioendothelioma is another intermediate-grade lesion not driven by HHV-8, and angiosarcoma is a high-grade, aggressive malignancy.

Kaposi Sarcoma: The HHV-8-Linked Vascular Tumor

Kaposi sarcoma is a vascular tumor with a distinctive connection to human herpesvirus 8 (HHV-8). It can grow in the skin, mouth, lymph nodes, or internal organs, and its behavior ranges from slow and localized to more widespread disease. That range helps explain why it is often described as an intermediate-grade neoplasm: it is not simply a harmless collection of blood vessels, but it also does not behave like the most aggressive vascular cancers in every person.

The virus is central to the story, though it is not the whole story. Many people carry HHV-8 without developing Kaposi sarcoma. Immune status, age, geography, and other health factors all help shape what happens next.

A virus with a particular role

HHV-8 is also known as Kaposi sarcoma-associated herpesvirus. It belongs to the herpesvirus family, which includes viruses that can remain in the body for long periods. After infection, HHV-8 may persist in a quiet, latent state. In some cells, viral genes can affect how cells grow, survive, and interact with their surroundings.

Kaposi sarcoma develops from cells with features of endothelial cells—the cells that line blood and lymphatic vessels. HHV-8 infection is found in the tumor cells and is a defining feature of the disease. A viral protein called latent nuclear antigen, or LANA, can be detected in the nuclei of these cells. In tissue samples, LANA is a valuable marker that helps identify Kaposi sarcoma and separate it from other vascular tumors.

Still, finding HHV-8 does not mean that a person will develop cancer. The immune system usually helps keep the virus in check. When immune defenses weaken, infected cells may gain more room to grow. This is one reason Kaposi sarcoma is strongly associated with advanced HIV infection and with medicines that suppress the immune system, such as those used after an organ transplant.

What “intermediate-grade” means

The term intermediate-grade describes a tumor whose behavior falls between clearly benign growths and highly aggressive cancers. Kaposi sarcoma may grow slowly for years, especially when it affects only the skin. In other cases, it can spread through the skin, involve lymph nodes, or affect organs such as the lungs and digestive tract.

That variation can make the label seem less tidy than it sounds. Grade describes broad patterns of behavior; it does not predict the exact course for every person. The extent of disease, the person’s immune health, and the form of Kaposi sarcoma all matter. A small skin lesion in one person and widespread disease in another share a name, but they may call for very different care.

What the tumor looks like

On the skin, Kaposi sarcoma often appears as flat or raised patches, plaques, or nodules. They may be red, purple, brown, or nearly black, depending on skin tone and the amount of blood and pigment in the tissue. Lesions can appear on the legs and feet, but they may occur elsewhere, including the face and inside the mouth.

Under a microscope, the tumor contains spindle-shaped cells—long cells with tapered ends—that grow in bundles. These cells form narrow, irregular spaces that resemble small slits. Red blood cells often spill into the surrounding tissue, and iron-containing hemosiderin can collect as the body breaks down the blood. Together, these findings help pathologists recognize the pattern.

No single visual clue tells the full story. Several vascular lesions can look similar, especially early on, so clinicians and pathologists consider the lesion’s appearance, location, growth pattern, and microscopic features. The presence of HHV-8 LANA in the tumor cells provides a particularly strong clue.

Four patterns, shaped by context

Kaposi sarcoma is commonly grouped into four forms. They share the same viral association, but their typical settings and courses differ.

  • Classic Kaposi sarcoma most often affects older adults, especially men from parts of the Mediterranean, Eastern Europe, or the Middle East. It commonly starts on the lower legs and may progress slowly.

  • Endemic Kaposi sarcoma occurs in parts of sub-Saharan Africa, where HHV-8 is common. Its features vary; some forms are relatively slow, while others affect younger people and can be more aggressive.

  • HIV-associated Kaposi sarcoma is linked to weakened immune function in people with HIV. It may involve the skin, mouth, lymph nodes, or internal organs.

  • Iatrogenic Kaposi sarcoma occurs when immune function is suppressed by medicines, often after an organ transplant. In some cases, changing the immune-suppressing treatment can help control the disease, though this decision must be weighed against the risk of organ rejection.

These categories are useful, but real lives do not always fit neatly into boxes. A person’s immune health and the location of the lesions help guide care more than the label alone.

How it differs from other vascular tumors

Kaposi sarcoma is not the only tumor that forms from, or resembles, blood-vessel tissue. Hemangioendothelioma is another group of vascular tumors with a range of behaviors, but it is not defined by HHV-8 infection. Angiosarcoma, by contrast, is a high-grade malignancy that can grow and spread aggressively. Pyogenic granuloma is a benign, often rapidly growing lesion made up of small blood vessels; despite its name, it is not a true granuloma and is not caused by pus.

The differences matter because a similar-looking mark can point to very different conditions. Kaposi sarcoma’s combination of spindle cells, slit-like vascular spaces, blood leakage, and HHV-8 LANA staining helps distinguish it. The wider clinical picture adds another layer: immune status and the presence of lesions in the mouth or organs can influence how clinicians assess the disease.

Symptoms depend on where it grows

Skin lesions may be painless, though they can swell, bleed, or cause discomfort. When the legs are affected, swelling can develop, particularly if lymphatic drainage is disrupted. Lesions inside the mouth may make eating or swallowing uncomfortable.

Internal disease can cause symptoms that are less obvious at first. Involvement of the digestive tract may lead to abdominal discomfort or bleeding. Lung involvement can cause breathlessness, cough, or chest symptoms. These signs are not unique to Kaposi sarcoma, which is why clinicians consider the full picture rather than relying on symptoms alone.

Diagnosis and care

Diagnosis usually begins with an examination and a biopsy, in which a small tissue sample is examined under a microscope. Pathologists assess the cell pattern and may use stains that detect HHV-8 LANA. Clinicians also consider the person’s immune health and whether the disease may involve areas beyond the skin.

Care depends on the extent of the tumor and the person’s overall health. Small, localized lesions may be managed with treatments directed at the affected area. More widespread disease may call for medicines that work throughout the body. For HIV-associated Kaposi sarcoma, effective HIV treatment can restore immune function and often helps control the tumor. For transplant-related disease, a specialist may consider adjusting immune-suppressing medicines.

There is no single plan for everyone. Some people need close monitoring, while others need prompt treatment for symptoms or organ involvement. The aim is to control the tumor while also protecting the person’s broader health.

Kaposi sarcoma stands out because it brings virology, immunity, and vascular biology together in one disease. HHV-8 provides a defining clue, but immune context shapes much of the course. Understanding both pieces makes the tumor’s intermediate-grade behavior easier to grasp: it can be indolent, serious, or somewhere between, depending on the person and the disease’s reach.